Korro Bio, INC 8-K filings

Korro Bio reported Q2 2026 results, highlighting progress on KRRO-121 and KRRO-111, receiving EMA Orphan Drug Designation, and maintaining a cash runway into late 2028.

Korro Bio stockholders elected two Class I directors, approved executive compensation, and ratified the appointment of Ernst & Young LLP.

Korro Bio announces KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency, showing promising preclinical results in restoring functional AAT protein.

Korro Bio announced first quarter 2026 financial results, highlighting significant scientific progress in its RNA editing platform and a corporate update including an $85 million private placement.

Korro Bio announced its full year 2025 financial results, highlighted by the nomination of a new development candidate KRRO-121 and an oversubscribed $85 million private placement extending its cash runway into the second half of 2028.

Korro Bio presented preclinical data for KRRO-121, a potential first-in-class treatment for hyperammonemia in Urea Cycle Disorders and Hepatic Encephalopathy, at its virtual Analyst Day.

Korro Bio, Inc. updated its corporate presentation, revealing a pipeline refresh, the termination of the REWRITE clinical trial for KRRO-110, and a 12-month pause in its Novo Nordisk collaboration.

Korro Bio, Inc. has amended its employment agreement with SVP, General Counsel & Secretary Jeffrey Cerio, increasing his salary and severance, and granting a cash bonus and restricted stock units as part of a retention program.

Korro Bio announced a strategic restructuring, including a workforce reduction and a 12-month pause in its collaboration with Novo Nordisk, following mixed results from its KRRO-110 clinical trial.

Korro Bio announced the resignation of Chief Financial Officer Vineet Agarwal, effective October 17, 2025, with President and CEO Ram Aiyar stepping in as interim Chief Financial Officer.

Korro Bio reported its second quarter 2025 financial results, highlighting progress in its KRRO-110 clinical trial for AATD and a strong cash position extending into 2027.

Korro Bio, Inc. announced that its Board of Directors has determined to hold annual non-binding advisory votes on executive compensation, aligning with the preference expressed by stockholders at the 2025 Annual Meeting.

Korro Bio, Inc. announced the results of its 2025 annual meeting, where stockholders re-elected three Class III directors, approved executive compensation, and ratified Ernst & Young LLP as its independent auditor.

Korro Bio reports its Q1 2025 financial results, provides business updates including progress on its KRRO-110 clinical trial, and announces a strategic streamlining of operations including a 20% workforce reduction to extend its cash runway into 2027.

Korro Bio announces the return of Vineet Agarwal as CFO from medical leave and the appointment of Oliver Dolan as principal accounting officer, effective March 27, 2025.

Korro Bio announces full year 2024 financial results, highlights clinical trial progress, and provides business updates, including a strong cash position and upcoming milestones.

Korro Bio appoints interim CFO and principal accounting officer as Vineet Agarwal takes temporary medical leave.

Korro Bio has initiated dosing in its Phase 1/2a clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and provided an update on its pipeline.

Korro Bio has secured approval to begin a Phase 1/2a clinical trial in Australia for its KRRO-110 treatment for Alpha-1 Antitrypsin Deficiency.

Korro Bio announced its third quarter 2024 financial results, highlighted by a regulatory filing for its lead candidate, a new clinical advisory board, and a partnership with Novo Nordisk.

Korro Bio has submitted its first regulatory filing for a Phase 1/2 clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) and formed a clinical advisory board.

Korro Bio has entered into a research collaboration and license agreement with Novo Nordisk, potentially worth up to $530 million, to develop RNA editing therapies for cardiometabolic diseases.

Korro Bio's board of directors experienced a resignation and a new appointment, along with a consulting agreement with the departing director.

Korro Bio announced its second quarter 2024 financial results, highlighted by a strong cash position and progress on its lead candidate, KRRO-110, for alpha-1 antitrypsin deficiency.

Korro Bio's Chief Scientific Officer, Steve Colletti, Ph.D., has announced his resignation, effective August 2, 2024.

Korro Bio's stockholders approved an amendment to the company's charter to limit the liability of certain officers and elected two Class II directors at their annual meeting on June 11, 2024.

Korro Bio has announced the appointment of Dr. Kemi Olugemo as its new Chief Medical Officer, effective May 13, 2024.

Korro Bio announced its first quarter 2024 financial results, the appointment of a new Chief Medical Officer, and the closing of a $70 million private placement, extending its cash runway into the second half of 2026.

Korro Bio successfully closed a $70 million private placement, led by Deep Track Capital, to fund clinical trials and platform development.

Korro Bio has successfully raised $70 million through a private placement to fund its clinical programs and platform development.